Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5957111 | 0.91 | P2RX7 (0.39) | P2RX7MAPTKDM4ELMNAHTT | |
| SCHEMBL5838361 | 0.90 | P2RX7 (0.36) | P2RX7MAPTKDM4ELMNAHTT | |
| SCHEMBL5837071 | 0.89 | P2RX7 (0.36) | P2RX7MAPTKDM4ECNR2 | |
| SCHEMBL5838594 | 0.88 | P2RX7 (0.45) | P2RX7KMT2ACNR1CNR2 | |
| SCHEMBL5837733 | 0.86 | P2RX7 (0.40) | P2RX7CNR1CNR2 | |
| SCHEMBL5838943 | 0.85 | P2RX7 (0.39) | P2RX7MAPTKDM4ELMNAHTT | |
| SCHEMBL5837666 | 0.85 | P2RX7 (0.39) | P2RX7CNR1CNR2 | |
| SCHEMBL5837257 | 0.84 | DRD2 (0.40) | P2RX7MAPTKMT2ACNR1CNR2 | |
| SCHEMBL5838177 | 0.84 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL5839202 | 0.83 | P2RX7 (0.38) | P2RX7KMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | DOMBROSKI MARK A | 2006-09-28 | — | — | US | disclosed |
| US-7071223-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1581507-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058731-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885MAPT 4029/4885KDM4E 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.